Novartis CEO sees China M&A hampered by data, regulatory standards
May 23, 2019U.S. home sales, manufacturing stumble; labor market strong
May 23, 2019Novartis CEO sees chance to accelerate profit margin target
at
Novartis could reach its main drugs business’s margin target “a little sooner” than 2022, as it now forecasts, as it cuts costs and as new drugs including gene therapy accelerate, Chief Executive Vas Narasimhan told investors.
Powered by WPeMatico
